Pazopanib for both GIST and soft-tissue sarcoma
Mené en France sur 81 patients atteints d'une tumeur stromale gastro-intestinale de stade avancé et résistante à l'imatinib et au sunitinib, cet essai multicentrique randomisé de phase II évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité du pazopanib
Sarcomas are rare mesenchymal tumours that account for nearly 1% of all adult cancers worldwide and comprise more than 50 different histological subtypes, including gastrointestinal stromal tumours (GIST). When not curable by surgery, medical therapy is indicated, but is limited by both the number of available treatments and their efficacy. Standard treatment options for soft-tissue sarcoma include cytotoxic chemotherapy with doxorubicin, ifosfamide, or both. Recently, pazopanib—a multitargeted angiogenesis inhibitor—has shown substantial activity against soft-tissue sarcoma, excluding adipocyte sarcomas, bone sarcomas, and GIST.
The Lancet Oncology , commentaire, 2015